ZA201803749B - Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method - Google Patents

Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method

Info

Publication number
ZA201803749B
ZA201803749B ZA2018/03749A ZA201803749A ZA201803749B ZA 201803749 B ZA201803749 B ZA 201803749B ZA 2018/03749 A ZA2018/03749 A ZA 2018/03749A ZA 201803749 A ZA201803749 A ZA 201803749A ZA 201803749 B ZA201803749 B ZA 201803749B
Authority
ZA
South Africa
Prior art keywords
carboxypropionyl
biphenyl
salts
amino
preparation
Prior art date
Application number
ZA2018/03749A
Inventor
Ales Halama
Pavel Zvatora
Michal Voslar
Jan Stach
Michal Zapadlo
Ondrej Dammer
Lukas Krejcik
Lenka Dvorakova
Marketa Rezankova
Rostislav Vyslouzil
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57614098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201803749(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2015-891A external-priority patent/CZ2015891A3/en
Priority claimed from CZ2015-896A external-priority patent/CZ2015896A3/en
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of ZA201803749B publication Critical patent/ZA201803749B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
ZA2018/03749A 2015-12-11 2018-06-06 Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method ZA201803749B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ2015-891A CZ2015891A3 (en) 2015-12-11 2015-12-11 The crystalline form of potassium salt of ethyl ester (2R,4S)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid and the industrially applicable method of its preparation
CZ2015-896A CZ2015896A3 (en) 2015-12-14 2015-12-14 The solid forms of the ethyl ester of (2R,4S)-5-(biphenyl-4-yl)-4-[3-carboxy-propionyl)amino]-2—methylpentanoic acid, its salts and the method of its preparation
PCT/CZ2016/000130 WO2017097275A1 (en) 2015-12-11 2016-12-12 Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method

Publications (1)

Publication Number Publication Date
ZA201803749B true ZA201803749B (en) 2019-04-24

Family

ID=57614098

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/03749A ZA201803749B (en) 2015-12-11 2018-06-06 Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method

Country Status (6)

Country Link
EP (1) EP3386945A1 (en)
BR (1) BR112018011788A2 (en)
CO (1) CO2018005941A2 (en)
MX (1) MX2018007129A (en)
WO (1) WO2017097275A1 (en)
ZA (1) ZA201803749B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109661386A (en) * 2016-09-07 2019-04-19 诺瑞特国际药业股份有限公司 Sha Ku is than bent sodium salt novel crystal forms
EP3522886A4 (en) 2016-10-10 2020-02-19 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
US10995060B2 (en) 2016-10-28 2021-05-04 Biocon Limited Amorphous Trisodium Sacubitril Valsartan and process for its preparation
CN107311909A (en) * 2017-06-22 2017-11-03 东南大学 A kind of preparation method of LCZ696 impurity reference substance
PL3658122T3 (en) 2017-07-28 2021-10-18 Synthon B.V. Pharmaceutical composition comprising sacubitril and valsartan
CN109400493B (en) * 2017-08-15 2021-07-09 成都博腾药业有限公司 Preparation method of Sacubitril and intermediate thereof
CN107602410A (en) * 2017-09-13 2018-01-19 浙江三门恒康制药有限公司 Sha Ku is than crystal formation II of bent sodium salt and preparation method thereof
CN108530371B (en) * 2017-12-27 2020-09-01 浙江天宇药业股份有限公司 Sacubitril sodium salt, eutectic compound of Sacubitril free acid and acetic acid, crystal form of Sacubitril free acid and preparation method and application of crystal form
CN108558693A (en) * 2018-04-24 2018-09-21 南京双科医药开发有限公司 The method that one planting sand library Ba Qu free acids and its metal salt are applied in medicine preparation
GB201810326D0 (en) * 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
CN109912486B (en) * 2019-04-25 2022-09-27 东北制药集团股份有限公司 Preparation method of biphenyl methyl lactam compound
CN110878039A (en) * 2019-12-18 2020-03-13 株洲千金药业股份有限公司 Preparation method of Sacubitril valsartan sodium impurity
CN115677521B (en) * 2022-11-16 2024-02-02 迪嘉药业集团股份有限公司 Preparation method of high-purity Sha Kuba koji calcium

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
RU2334513C3 (en) 2002-01-17 2017-10-24 Новартис Аг PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND NEUTRAL ENDOPEPTIDASE INHIBITORS (NEP)
WO2007045663A2 (en) 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (en) 2005-11-09 2007-12-26 Novartis Ag DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
LT2121578T (en) 2007-01-12 2016-11-25 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
PE20091364A1 (en) 2008-01-17 2009-10-13 Novartis Ag PROCESS FOR THE PREPARATION OF NEP INHIBITORS
PT2526088E (en) 2010-01-22 2015-11-03 Novartis Ag Intermediates of neutral endopeptidase inhibitors and preparation method thereof
EP2609071B1 (en) 2010-08-23 2016-09-21 Novartis AG New process for the preparation of intermediates useful for the manufacture of nep inhibitors
KR101476937B1 (en) 2010-08-23 2014-12-24 노파르티스 아게 Process for the preparation of intermediates for the manufacture of nep inhibitors
AR092278A1 (en) 2012-08-31 2015-04-08 Novartis Ag PROCESS FOR OBTAINING N-ACILIC DERIVATIVES OF BIFENYL-ALANINE AND RELATED INTERMEDIARIES
US20160206597A1 (en) 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
WO2016029828A1 (en) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 Crystalline free acid, hemicalcium salt and α-phenylethylamine salt of ahu-377 as well as preparation method therefor and application thereof
CN105622452A (en) * 2014-08-27 2016-06-01 上海翰森生物医药科技有限公司 AHU-377 crystal-type free acid, preparation method and applications thereof
CN105461587A (en) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 AHU-377 hemicalcium salt crystal form, preparation method and application thereof
PL3218351T3 (en) * 2014-11-14 2019-12-31 Zentiva K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
CN105837464A (en) * 2015-01-15 2016-08-10 四川海思科制药有限公司 Sacubitril sodium crystal forms, preparation method and application thereof

Also Published As

Publication number Publication date
BR112018011788A2 (en) 2018-12-04
EP3386945A1 (en) 2018-10-17
WO2017097275A1 (en) 2017-06-15
MX2018007129A (en) 2018-11-09
CO2018005941A2 (en) 2018-07-10

Similar Documents

Publication Publication Date Title
ZA201803749B (en) Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
IL258636A (en) Acc inhibitors and uses thereof
EP3331530A4 (en) Mthfd2 inhibitors and uses thereof
HUE053175T2 (en) Ester acc inhibitors and uses thereof
IL287604A (en) Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
EP3284738A4 (en) 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
HK1245772A1 (en) (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
EP3292860A4 (en) Cabazitaxel fat emulsion injection, and preparation method and use thereof
IL253601B (en) (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
IL258820A (en) System and method for suture knot forming
PT3621948T (en) Amino (meth)acrylates
SG11201707248XA (en) Management system and management method for packages of shuffled playing cards
EP3389664A4 (en) Caffeine inhibitors of mthfd2 and uses thereof
PL3448946T3 (en) Method for the preparation of organopolysiloxanes having (meth)acrylate functions
HK1245094A1 (en) Pharmaceutical composition for treatment of depression and preparation method thereof
HK1246172A1 (en) Amino acid-containing external skin preparation for face
EP3258858A4 (en) Improved banding device for treating hemmorrhoids and reloading device
HK1244224B (en) Pharmaceutical composition of mek inhibitor and preparation method thereof
SI3408264T1 (en) Nilotinib dinitrate (v) and crystalline forms thereof
IL255024A0 (en) Hydroxamic acids and uses thereof
GB201504936D0 (en) Suture anchor delivery tool
GB201621139D0 (en) Agent and method for temporarily deforming keratin-containing fibers
GB201621141D0 (en) Agent and method for temporarily deforming keratin-containing fibers
HUE051157T2 (en) Composition containing acrylic acid derivative, and method for stabilizing acrylic acid derivative
EP3156051A4 (en) Pharmaceutical composition combining an anticonvulsant and a derivate of nicotinic acid